Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 3953

1.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
[PubMed - indexed for MEDLINE]
2.

[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].

Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.

Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9. German.

PMID:
18709375
[PubMed - indexed for MEDLINE]
3.

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF.

Arch Ophthalmol. 2007 Sep;125(9):1249-54.

PMID:
17846366
[PubMed - indexed for MEDLINE]
4.

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.

Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300 . Epub 2008 Jun 10.

PMID:
18547463
[PubMed - indexed for MEDLINE]
5.

[Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].

Soubrane G, Zlateva G, Xu X, Buggage R, Kosa M.

J Fr Ophtalmol. 2008 Feb;31(2):138-45. French.

PMID:
18401314
[PubMed - indexed for MEDLINE]
Free Article
6.

Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.

Pharmacoeconomics. 2006;24(2):193-205.

PMID:
16460138
[PubMed - indexed for MEDLINE]
7.

Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.

Drugs Aging. 2008;25(3):255-68.

PMID:
18331076
[PubMed - indexed for MEDLINE]
8.

Burden of illness of neovascular age-related macular degeneration in Canada.

Cruess A, Zlateva G, Xu X, Rochon S.

Can J Ophthalmol. 2007 Dec;42(6):836-43.

PMID:
18026200
[PubMed - indexed for MEDLINE]
9.
10.

Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.

Coleman AL, Yu F.

Ophthalmology. 2008 Jan;115(1):18-25. Epub 2007 Jun 18.

PMID:
17572499
[PubMed - indexed for MEDLINE]
11.

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11.

PMID:
19669678
[PubMed - indexed for MEDLINE]
12.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17.

PMID:
18179676
[PubMed - indexed for MEDLINE]
13.

The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Bonastre J, Le Pen C, Soubrane G, Quentel G.

Pharmacoeconomics. 2003;21(3):181-90.

PMID:
12558468
[PubMed - indexed for MEDLINE]
14.

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.

PMID:
17887807
[PubMed - indexed for MEDLINE]
15.

The economic impact of overactive bladder syndrome in six Western countries.

Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C.

BJU Int. 2009 Jan;103(2):202-9. doi: 10.1111/j.1464-410X.2008.08036.x.

PMID:
19278532
[PubMed - indexed for MEDLINE]
16.

The burden of age-related macular degeneration.

Schmier JK, Jones ML, Halpern MT.

Pharmacoeconomics. 2006;24(4):319-34. Review.

PMID:
16605279
[PubMed - indexed for MEDLINE]
17.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

PMID:
18462575
[PubMed - indexed for MEDLINE]
Free Article
18.

[Methods for estimating personal costs of disease using retinal diseases as an example].

Porz G, Scholl HP, Holz FG, Finger RP.

Ophthalmologe. 2010 Mar;107(3):216-20, 222. doi: 10.1007/s00347-009-2036-8. German.

PMID:
20195614
[PubMed - indexed for MEDLINE]
19.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
[PubMed - indexed for MEDLINE]
20.

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, Chen PP, Coleman AL, Feldman RM, Jampel HD, Katz LJ, Mills RP, Myers JS, Noecker RJ, Piltz-Seymour JR, Ritch RR, Schacknow PN, Serle JB, Trick GL.

Arch Ophthalmol. 2006 Jan;124(1):12-9.

PMID:
16401779
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk